Abstract
Background: Anemia during the first 12 week of therapy is the most common side effect of pegylated interferon (PegIFN)/ribavirin (RBV) and telaprevir (TVR) in HCV genotype 1 patients with advanced fibrosis or cirrhosis (F3–F4). Inosine triphosphatase (ITPA) genetic variants are associated with RBV-induced anemia and dose reduction but their role as predictors of anemia during TVR therapy is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
